Gilead Sciences acquires cancer biotech Tubulis

Gilead Sciences is set to acquire German biotech firm Tubulis GmbH for up to $5 billion. This strategic move aims to bolster Gilead's oncology portfolio by integrating Tubulis's innovative cancer drug development capabilities. The acquisition reflects a significant investment in a rapidly advancing field, signaling Gilead's commitment to expanding its presence and pipeline in the competitive landscape of cancer therapeutics.